Research & Clinical Evidence
Cognitive Leap® builds on clinical evidence. Every solution is validated through rigorous studies, with results published and presented at leading academic institutions.
Completed Studies
US Clinic Outcomes Report — February 2026
n=49 • Location: Cogleap® centers in Irvine and Palo Alto, CA • Population: children ages 4–18 (55% autism, 8% ADHD, 14% autism + ADHD)
Key Insights:
Autism Differential Response Study 2025
n=33 • Focus: Neurotype-specific treatment response
Key Insights:
Autistic children show the strongest gains in motor skills. Non-autistic children show the strongest gains in attention and executive function. This validates our precision-medicine approach.
Sun Yat-sen University RCT 2025
n=100 • Design: Randomized controlled trial • Location: Sun Yat-sen University, Shenzhen
Key Insights:
Statistically significant improvements in SNAP-IV and SDQ scores (clinic-based group). 100% recruitment feasibility. Significant improvements in attention, hyperactivity, and conduct.
Stanford Neurodiversity Summit 2024
n=58 • Location: Cogleap® US centers (Irvine, Palo Alto) • Population: children ages 5–18 with ADHD or autism
Key Insights:
Academic Relationships
Stanford Medicine
Advisory relationship; outcomes presented at the Neurodiversity Summit 2024
Duke University
Global testing partnership for assessment validation
Palo Alto University
Practicum site for clinical psychology training
Sun Yat-sen University
Formal clinical trial partnership, School of Public Health
